切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2023, Vol. 17 ›› Issue (02) : 217 -220. doi: 10.3877/cma.j.issn.1674-3946.2023.02.026

综述

外周血非编码RNA在胰腺癌中研究进展
李泽乾1, 郝少龙1, 张博1, 纪凯伦1, 韩威1,()   
  1. 1. 101100 北京,首都医科大学附属北京潞河医院普通外科
  • 收稿日期:2022-10-09 出版日期:2023-04-26
  • 通信作者: 韩威

Research progress of peripheral blood non-coding RNA in pancreatic cancer

Zeqian Li1, Shaolong Hao1, Bo Zhang1, Kailun Ji1, Wei Han1,()   

  1. 1. Department of General Surgery, Beijing Luhe Hospital, Capital Medical University, Beijing 101100, China
  • Received:2022-10-09 Published:2023-04-26
  • Corresponding author: Wei Han
  • Supported by:
    Capital’s Funds for Health Improvement and Research(CFH-2022-2-7081); Beijing Tongzhou District Science and Technology Project(KJ2022CX016)
引用本文:

李泽乾, 郝少龙, 张博, 纪凯伦, 韩威. 外周血非编码RNA在胰腺癌中研究进展[J]. 中华普外科手术学杂志(电子版), 2023, 17(02): 217-220.

Zeqian Li, Shaolong Hao, Bo Zhang, Kailun Ji, Wei Han. Research progress of peripheral blood non-coding RNA in pancreatic cancer[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 217-220.

胰腺癌是恶性程度高的消化系统肿瘤,随着非编码RNA在胰腺癌中的研究不断深入,发现非编码RNA具有作为诊断胰腺癌生物标志物和治疗靶点的重要潜能。外周血非编码RNA的检测更是因简便、非侵入性等优势而深受广大研究者的青睐。通过搜集近些年来外周血非编码RNA与胰腺癌的相关研究,本文将从微小RNA(miRNA)、长链非编码RNA(lncRNA)和环状RNA(circRNA)三方面对外周血非编码RNA在胰腺癌诊疗中的研究进展作一综述。

Pancreatic cancer is a digestive system tumor with a high degree of malignancy. With the deepening of research on non-coding RNA in pancreatic cancer,it has been found that non-coding RNA has important potential as biomarkers and therapeutic targets in the diagnosis of pancreatic cancer. The detection of peripheral blood non-coding RNA is favored by the majority of researchers because of its simplicity and non-invasive advantages. By collecting relevant studies on peripheral blood non-coding Rnas and pancreatic cancer in recent years,this paper reviews the research progress of peripheral blood non-coding Rnas in the diagnosis and treatment of pancreatic cancer from the perspectives of micrornas(mirnas),long-chain non-coding Rnas(lncrnas)and circrnas.

[1]
Ilic MIlic I. Epidemiology of pancreatic cancer[J]. World J Gastroenterol201622(44):9694-9705.
[2]
Vincent AHerman JSchulick R,et al. Pancreatic cancer[J]. Lancet2011378(9791):607-620.
[3]
赵建国,廖泉,赵玉沛. 胰腺癌分子标志物研究进展[J/CD]. 中华普外科手术学杂志(电子版)20137(03):224-226.
[4]
Huang JLiu JChen-Xiao K,et al. Advance in microRNA as a potential biomarker for early detection of pancreatic cancer[J]. Biomark Res20164:20.
[5]
Chandra Gupta SNandan Tripathi Y. Potential of long non-coding RNAs in cancer patients:From biomarkers to therapeutic targets[J]. Int J Cancer2017140(9):1955-1967.
[6]
谢雨婷,高军. 微小RNA在胰腺癌诊断中的研究进展[J]. 中华胰腺病杂志202222(02):148-152.
[7]
Schultz NADehlendorff CJensen BV,et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer[J]. JAMA2014311(4):392-404.
[8]
Chen JYao DChen W,et al. Serum exosomal miR-451a acts as a candidate marker for pancreatic cancer[J]. Int J Biol Markers202237(1):74-80.
[9]
Yang JXu RWang C,et al. Early screening and diagnosis strategies of pancreatic cancer:a comprehensive review[J]. Cancer Commun(Lond)202141(12):1257-1274.
[10]
Szafranska-Schwarzbacht AEAdai ATLee LS,et al. Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma[J]. Expert Rev Mol Diagn201111(3):249-257.
[11]
Morimura RKomatsu SIchikawa D,et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer[J]. Br J Cancer2011105(11):1733-1740.
[12]
Kawaguchi TKomatsu SIchikawa D,et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer[J]. Br J Cancer2013108(2):361-369.
[13]
Liang LWei DMLi JJ,et al. Prognostic microRNAs and their potential molecular mechanism in pancreatic cancer:A study based on The Cancer Genome Atlas and bioinformatics investigation[J]. Mol Med Rep201817(1):939-951.
[14]
Muro KFuchs CSJang RWJ,et al. KEYNOTE-059 cohort 1:Pembrolizumab(Pembro)monotherapy in previously treated advanced gastric or gastroesophageal junction(G/GEJ)cancer in patients(Pts)with PD-L1+tumors-Asian subgroup analysis[J]. J Clinical Onc201836(4):1.
[15]
Wang PZhuang LZhang J,et al. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer,and miR-21 expression confers chemoresistance by targeting FasL[J]. Mol Oncol20137(3):334-345.
[16]
Gisel AValvano MEl Idrissi IG,et al. miRNAs for the Detection of MultiDrug Resistance:Overview and Perspectives[J]. Molecules 201419(5):5611-5623.
[17]
Jung HErtl LJanson C,et al. Inhibition of CCR2 potentiates the checkpoint inhibitor immunotherapy in pancreatic cancer[J]. Cancer Immunol Res20164(11):1123.
[18]
Lu YLu JLi X,et al. MiR-200a inhibits epithelial-mesenchymal transition of pancreatic cancer stem cell[J]. BMC Cancer201414:85.
[19]
Ma CHuang TDing YC,et al. microRNA-200c overexpression inhibits chemoresistance,invasion and colony formation of human pancreatic cancer stem cells[J]. Int J Clin Exp Pathol20158(6):6533-6539.
[20]
Singh SChitkara DKumar V,et al. miRNA profiling in pancreatic cancer and restoration of chemosensitivity[J]. Cancer Lett2013334(2):211-220.
[21]
Mittal AChitkara DBehrman SW,et al. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer[J]. Biomaterials201435(25):7077-7087.
[22]
Sicard FGayral MLulka H,et al. Targeting miR-21 for the Therapy of Pancreatic Cancer[J]. Mol Ther201321(5):986-994.
[23]
Huarte M. The emerging role of lncRNAs in cancer[J]. Nat Med201521(11):1253-1261.
[24]
Wang YLi ZZheng S,et al. Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers[J]. Oncotarget20156(34):35684-35698.
[25]
Li LZhang GQChen H,et al. Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer[J]. Oncotarget20167(44):71773-71781.
[26]
Lu HYang DZhang L,et al. Linc-pint inhibits early stage pancreatic ductal adenocarcinoma growth through TGF-beta pathway activation[J]. Oncol Lett201917(5):4633-4639.
[27]
Liu YFeng WLiu W,et al. Circulating lncRNA ABHD11-AS1 serves as a biomarker for early pancreatic cancer diagnosis[J]. J Cancer201910(16):3746-3756.
[28]
Lu HYe JZhang L,et al. Downregulation of LINC01638 lncRNA inhibits migration and invasion of pancreatic ductal adenocarcinoma cells by reducing TGF-beta signaling[J]. Mol Med Rep201920(5):4533-4539.
[29]
Takahashi KOta YKogure T,et al. Circulating extracellular vesicle-encapsulated HULC is a potential biomarker for human pancreatic cancer[J]. Cancer Sci2020111(1):98-111.
[30]
Pan SShen MZhou M,et al. Long noncoding RNA LINC01111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924[J]. Cell Death Dis201910(12):883.
[31]
Li ZZhao XZhou Y,et al. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer[J]. J Transl Med201513:84.
[32]
You LWang HYang G,et al. Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207[J]. Mol Oncol201812(12):2147-2164.
[33]
Gonzalez-Duarte ABerk JLQuan D,et al. Analysis of autonomic outcomes in APOLLO,a phase Ⅲ trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis[J]. J Neurol2020267(3):703-712.
[34]
Zhen SLi X. Application of CRISPR-Cas9 for Long Noncoding RNA Genes in Cancer Research[J]. Hum Gene Ther201930(1):3-9.
[35]
Yang FLiu DYGuo JT,et al. Circular RNA circ-LDLRAD3 as a biomarker in diagnosis of pancreatic cancer[J]. World J Gastroenterol201723(47):8345-8354.
[36]
Xu YYao YGao P,et al. Upregulated circular RNA circ_0030235 predicts unfavorable prognosis in pancreatic ductal adenocarcinoma and facilitates cell progression by sponging miR-1253 and miR-1294[J]. Biochem Biophys Res Commun2019509(1):138-142.
[37]
Hao LRong WBai L,et al. Upregulated circular RNA circ_0007534 indicates an unfavorable prognosis in pancreatic ductal adenocarcinoma and regulates cell proliferation,apoptosis,and invasion by sponging miR-625 and miR-892b[J]. J Cell Biochem2019120(3):3780-3789.
[38]
Xu CYu YDing F. Microarray analysis of circular RNA expression profiles associated with gemcitabine resistance in pancreatic cancer cells[J]. Oncol Rep201840(1):395-404.
[39]
Liu YXia LDong L,et al. CircHIPK3 Promotes Gemcitabine(GEM)Resistance in Pancreatic Cancer Cells by Sponging miR-330-5p and Targets RASSF1[J]. Cancer Manag Res202012:921-929.
[1] 韩丹, 王婷, 肖欢, 朱丽容, 陈镜宇, 唐毅. 超声造影与增强CT对儿童肝脏良恶性病变诊断价值的对比分析[J]. 中华医学超声杂志(电子版), 2023, 20(09): 939-944.
[2] 郏亚平, 曾书娥. 含鳞状细胞癌成分的乳腺化生性癌的超声与病理特征分析[J]. 中华医学超声杂志(电子版), 2023, 20(08): 844-848.
[3] 钱龙, 陆晓峰, 王行舟, 杜峻峰, 沈晓菲, 管文贤. 神经系统调控胃肠道肿瘤免疫应答研究进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 86-89.
[4] 曹长青, 郭新艳, 高源, 张存, 唐海利, 樊东, 杨小军, 张松, 赵华栋. 肿瘤微环境参与介导HER2阳性乳腺癌曲妥珠单抗耐药的研究进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 90-95.
[5] 姚宏伟, 魏鹏宇, 高加勒, 张忠涛. 不断提高腹腔镜右半结肠癌D3根治术的规范化[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 1-4.
[6] 杜晓辉, 崔建新. 腹腔镜右半结肠癌D3根治术淋巴结清扫范围与策略[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 5-8.
[7] 周岩冰, 刘晓东. 腹腔镜右半结肠癌D3根治术消化道吻合重建方式的选择[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 9-13.
[8] 唐旭, 韩冰, 刘威, 陈茹星. 结直肠癌根治术后隐匿性肝转移危险因素分析及预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 16-20.
[9] 张生军, 赵阿静, 李守博, 郝祥宏, 刘敏丽. 高糖通过HGF/c-met通路促进结直肠癌侵袭和迁移的实验研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 21-24.
[10] 张焱辉, 张蛟, 朱志贤. 留置肛管在中低位直肠癌新辅助放化疗后腹腔镜TME术中的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 25-28.
[11] 李凤仪, 李若凡, 高旭, 张超凡. 目标导向液体干预对老年胃肠道肿瘤患者术后血流动力学、胃肠功能恢复的影响[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 29-32.
[12] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[13] 燕速, 霍博文, 徐惠宁. 4K荧光腹腔镜扩大右半结肠CME+D3根治术及No.206、No.204组淋巴结清扫术[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 14-14.
[14] 王军, 刘鲲鹏, 姚兰, 张华, 魏越, 索利斌, 陈骏, 苗成利, 罗成华. 腹膜后肿瘤切除术中大量输血患者的麻醉管理特点与分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 844-849.
[15] 徐军, 姬园园, 陈君平, 王健. 伴菊形团结构的脑膜瘤合并颅骨侵犯一例并文献复习[J]. 中华临床医师杂志(电子版), 2023, 17(08): 916-919.
阅读次数
全文


摘要